伊伐布雷定在心律失常中的研究进展  

Research progress of ivabradine in arrhythmia

作　　者：徐腾琪 王小飞[2] XU Teng-qi;WANG Xiao-fei(The First Central Clinical College of Tianjin Medical University,Tianjin 300070,China;International Medical Center of Tianjin First Central Hospital,Tianjin 300192,China)

机构地区：[1]天津医科大学一中心临床学院,天津300070 [2]天津市第一中心医院国际诊疗中心,天津300192

出　　处：《中国新药杂志》2023年第9期911-915,共5页Chinese Journal of New Drugs

基　　金：天津市卫生健康科技项目(ZC20159)。

摘　　要：心律失常的药物治疗一直存在许多不确定性。伊伐布雷定是一种新型药物,除了具有降低心率而不影响血流动力学的特点以外,还具有潜在的抗心律失常益处。然而,由于其潜在的致心律失常风险,目前尚未被批准用于除窦性心律失常以外的心律失常治疗。在本综述中,我们分别总结了伊伐布雷定用于窦性、房性、交界性及室性心律失常中的基础及临床研究证据,其对于窦性心律失常以外的其他类型心律失常的益处是否大于风险,目前尚无定论,需要更多研究进一步支持。There has been much uncertainty existing in the pharmacological treatment of cardiac arrhythmias.Ivabradine is a novel drug with potential anti-arrhythmic benefits in addition to its ability of reducing heart rate without affecting hemodynamics.However,it is not currently approved for the treatment of arrhythmias other than sinus arrhythmias because of its potential arrhythmogenic risk.This review summarizes the evidence from basic and clinical studies regarding the use of ivabradine in sinus,atrial,junctional,and ventricular arrhythmias.Whether its benefits outweigh the risks for other types of arrhythmias except sinus arrhythmias is inconclusive and needs further proofs from additional studies.

关 键 词：伊伐布雷定 心律失常 抗心律失常药物 研究进展 

分 类 号：R961[医药卫生—药理学]